J. Arron
Physiology · 2009–2013
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Physiology — 46 citations into it
- Immunology — 21 citations into it
- Surgery — 11 citations into it
Whom J. Arron trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- G. Anderson (in Physiology)
Papers from J. Arron's perspective
Ordered by how strongly the researchers J. Arron trusts endorse each paper. Same corpus, a different order for every researcher.
- Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. (American Journal of Respiratory and Critical Care Medicine)
- Evidence of a role of tumor necrosis factor alpha in refractory asthma. (New England Journal of Medicine)
- Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. (The Lancet)
- Inflammatory subtypes in asthma: Assessment and identification using induced sputum (Respirology (Carlton South. Print))
- Bioconductor: open software development for computational biology and bioinformatics (Genome Biology)
- Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. (New England Journal of Medicine)
- The development of allergic inflammation (Nature)
- Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. (The Lancet)
- Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma (New England Journal of Medicine)
- Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. (Journal of Allergy and Clinical Immunology)
Their papers
- Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. (2013) — 867 citations
- Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients (2012) — 626 citations
- Lebrikizumab treatment in adults with asthma. (2011) — 1,441 citations
- T-helper type 2-driven inflammation defines major subphenotypes of asthma. (2009) — 1,732 citations